Exciting news from
#ECCO2022
: upadacitinib, guselkumab, mirikizumab, risankizumab, filgotinib, ozanimod, etrasimod: all working in
#IBD
. Very good prospects, problems will be mainly three: predicting, choosing, and, particularly, access.
@geteccu
#somosGETECCU